

# Vaccine R&D and Manufacturing Eco- systems in Africa for Equitable Health Impact

Saul Walker

Acting Executive Director, Policy, Partnerships and Access

Dem Ausschuss ist das vorliegende Dokument  
in nicht barrierefreier Form zugeleitet worden.

# CEPI 2.0

## Vision statement

A world in which epidemics and pandemics are no longer a threat to humanity

## Mission statement

Accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need




## Prepare

for known epidemic and pandemic threats



## Transform

the response to the next novel threat



## Connect


to enhance and expand global collaboration

**100**  
day  
mission

To develop a safe and effective vaccine in 100 days from the moment that a pathogen is sequenced and/or the need for a vaccine is recognised to initial availability for use.

# CEPI Vaccine Manufacturing Partners in Africa

1. **Empower LMIC manufacturers** with tech transfer support, scale-/ramp-up as **long-term investment** supporting **geo-diversification** and improving local, regional and global public health security
2. **High performing entities** that have demonstrated competencies in scale-up and GMP production
3. **Strengthen capabilities for emergency response**



## Enabling Activities:

- **Implementing partnerships** with IVI AVEC and PATH
- **Global South Fellowship program**
- **Supply Chain support** e.g. matchmaking, modelling with KUL/ZEPAL, Supply Chain Forum event
- **Workforce training activities** e.g. lectures for African Vaccinology course, ACDC Internship programme
- **Publications** on best practice guidance for tech transfer and CMC aspects
- **Reagents and assay standards** development and supply
- **CEPI hosts RVMC**

# RVMC 2.0 and CEPI


RVMC's goal is to improve vaccine and health equity, health security, and economic development

Support **regional leadership** to establish sustainable vaccine manufacturing and supply chain networks that produce vaccines for **routine** use and are **ready for outbreak manufacturing** in support of the 100-Day Mission.

RVMC will focus on the following roles:

- **Advocate:** develop evidence base and advocate for regional vaccine manufacturing eco-systems using
- **Align:** support strategic and coherent alignment of vaccine manufacturing resources and investment
- **Advise:** independent, trusted advice to stakeholders.
- **Account:** monitor progress in regions across the pillars of the Framework.
- **CEPI/RVMC** – complementary to CEPI investment in **R&D eco-systems** and **manufacturing facilities**
- CEPI hosts RVMC and providing funding support for 3 years.

The RVMC Framework outlines the challenges and opportunities in developing regionalized vaccine manufacturing capacity across eight pillars which are the building blocks to establishing a sustainable ecosystem.



# Supply/Demand and Push/Pull Investments

## **Economically sustainable business models**

- Routine vaccine production as core business that can support emergency flex capacity
- New vaccine technologies (e.g. mRNA) do not yet have routine vaccine products
- R&D pipeline needed for more routine products on rapid response technologies
- Africa R&D eco-system for products with regional public health relevance

## **AVMA**

- Demand side investment to establish routine vaccine market as core business foundation
- Incentivises introduction of vaccines on new technologies

## **CEPI**

- Push investments in manufacturing partners, process innovation and enabling environment improve efficiency and reliability
- Product pipeline and investment in African R&D capacity for long-term eco-system

CEPI